Navigation Links
Sanofi Pasteur Commends Winners of International BioGENEius Challenge
Date:6/28/2011

SWIFTWATER, Pa., June 28, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), offers its congratulations to the four winners of the International BioGENEius Challenge, a competition for high school students who demonstrate an exemplary understanding of biotechnology through science research projects.

Sanofi Pasteur has sponsored the International BioGENEius Challenge since its inception in the early 1990s. Sanofi Pasteur scientists also served as judges for the US finals and the International finals competitions that were held during the BIO International Convention, which is the largest global event for the biotechnology industry, attracting between 14,000 and 20,000 attendees each year.

"Tomorrow's scientific discoveries depend upon society's ability to develop scientists today," notes Damian Braga, Sanofi Pasteur's senior vice president, global commercial operations, vaccines.  "Science-based corporations need to do all we can to encourage and support young students' interest in the sciences and this competition is one way to do that."

The 2011 winners of the International BioGENEius Challenge are:

First place – Prarthana Dalal from Shawnee Mission East High School in Leawood, Kan. Her project was Modeling of human non-deletional hereditary persistence of fetal hemoglobin (HPFH) conditions in Beta-globin locus transgenic mouse models: The -175 (T to C) and -195 (C to G) A-gamma globin gene point mutations.

Second place – Nathan Kondamuri from Munster High School in Dyer, Ind. His project was A Novel Biofuel Cell Based On Direct Electron Transfer-Type Bioelectrocatalysis Incorporating the Efficient System of Photophosphorylation.

Third place – David Campeau from Mayo High School in Rochester, Minn. His project was Brain Computer Interface.

Fourth place – Jenna Pappalardo from Satellite High School in Merritt Island, Fla. Her project was Meddling with RGS17.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


'/>"/>
SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi Announces Positive Results from the "All to Target" Study Evaluating Two Lantus® and Apidra® Regimens Versus Premixed Regimen
2. Medco, United BioSource and Sanofi Signed Global Agreement to Improve Quality of Patient Care Through Real-World Evidence
3. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
4. Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims
5. sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
6. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
7. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
8. Sanofi-Aventis Completes Acquisition of Genzyme Corporation
9. Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
10. Navinta LLC is Pleased to Announce US FDA Approval of Sodium Ferric Gluconate Injection in Sucrose [a generic equivalent of Ferrlecit® Injection by Sanofi Aventis] Based on Its Proprietary Technology
11. Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)...  Avista Pharma Solutions ("Avista Pharma") announced today that ... Officer (CFO). Mr. Setzer is a finance and operations ... roles within growing technology and life science companies. Prior ... Director of Finance at INC Research, a publicly traded ... . Previously, Mr. Setzer served as CFO of Expression ...
(Date:2/8/2016)... 8, 2016 Vestagen Technical Textiles, Inc., a ... for healthcare and other demanding applications, today announced it ... He replaces Dale Pfost , PhD, who was ... is also joining Vestagen,s Board of Directors. ... active barrier technologies that combines fluid repellent, antimicrobial and ...
(Date:2/8/2016)... 8, 2016  Astellas Pharma Inc. President and Chief Executive ... James Robinson as president, Americas Operations, for Astellas ... and South America , effective April 1, ... the commercial organization in the United States ... Masao Yoshida , who is retiring in June 2016.  ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 2016 , ... If you are feeling that your clothes are a tad ... to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women ... of cancer, some of the leading causes of preventable death. February is heart ...
(Date:2/8/2016)... ... 2016 , ... Delta Dental of California and its affiliated companies announced today ... Radine, who recently retired as president and CEO of Delta Dental of California and ... the Year , helped lead the effort to raise funds for studies to strengthen ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show ... to see the most incredible gardens and home improvement experts that attend this amazing ... Center - 700 14th St. Denver CO, is an exciting event that Performance Mobility ...
(Date:2/8/2016)... ... 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated ... his birthday on February 10th. During this time, people can achieve better health, ... 250,000 people from over 40 different countries as an “ordinary man with an extraordinary ...
(Date:2/7/2016)... Dallas, Texas (PRWEB) , ... February 07, 2016 ... ... its new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and ... , MyDecision™ combines three elements to cut the cost of providing employee healthcare ...
Breaking Medicine News(10 mins):